Hovione invests in filling for inhalable drugs

- Last updated on GMT

Related tags: Pharmacology

Hovione invests in filling for inhalable drugs
Hovione invests in filling for inhalable drugs
Hovione says demand drove acquisition of new capsule filling technology for inhalable drug products.

The Portugal-based firm installed a FlexaLAb filling system at its facility in Lisbon, explaining that the technology will support the production of drugs for Phase II and III trials but did not name the customer involved.

Company VP Peter Villax said: “We give our customers an edge in inhalation capsule filling for drug delivery to the lung, by providing access to a machine capable of very high precision filling of low doses, down to 5 mg.

We are perhaps the only independent company with expertise in every aspect of the inhaled drug development process and this acquisition strengthens our commitment to inhalation drug development​.”

The investment follow just over a year after Hovione added particle engineering capabilities to its contracting offering, initially through a technology investment​ and subsequently in partnership with Solvias​.

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Related suppliers

Follow us

Products

View more

Webinars